<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01689376</url>
  </required_header>
  <id_info>
    <org_study_id>16040</org_study_id>
    <nct_id>NCT01689376</nct_id>
  </id_info>
  <brief_title>Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)</brief_title>
  <official_title>Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed&#xD;
      with metastatic and / or unresectable GIST who have progressed after standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This &quot;Managed Access Program&quot; covers the different types of programs in the participating&#xD;
      countries (including compassionate use program, named patient program, cohorts e.g. ATU in&#xD;
      France, etc).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (BAY73-4506)</intervention_name>
    <description>160 mg BAY73-4506, 3 weeks on drug, 1 week off drug</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed consent (IC) and data protection clarification obtained before any&#xD;
             specific treatment related procedures. Patients or their legal representative must be&#xD;
             able to understand and willing to sign a written IC.&#xD;
&#xD;
          -  Male or female patients &gt;= 18 years of age&#xD;
&#xD;
          -  Patients with histologically confirmed metastatic and / or unresectable GIST&#xD;
&#xD;
          -  At least imatinib and sunitinib as prior treatment regimens with progression on or&#xD;
             intolerance to imatinib and sunitinib&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of =&lt; 1&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             before entering the program until at least 8 weeks after the last regorafenib&#xD;
             administration in the program. The treating physician or a designated associate is&#xD;
             requested to advise the patient on how to achieve adequate birth control. Adequate&#xD;
             contraception is defined in this program as any medically recommend method (or&#xD;
             combination of methods) as per standard of care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with regorafenib&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to starting regorafenib&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             pregnancy test performed a maximum of 7 days before start of treatment, and a negative&#xD;
             result must be documented before start of regorafenib.&#xD;
&#xD;
          -  Congestive heart failure New York Heart Association (NYHA) class 2&#xD;
&#xD;
          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3&#xD;
             months)&#xD;
&#xD;
          -  Myocardial infarction less than 6 months before start of regorafenib&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are&#xD;
             permitted)&#xD;
&#xD;
          -  Uncontrolled hypertension. (Systolic blood pressure &gt; 140 mmHg or diastolic pressure &gt;&#xD;
             90 mmHg despite optimal medical management)&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (National Cancer&#xD;
             Institute's common terminology criteria for adverse events [NCI-CTCAE] v.4.0 Grade &gt;=&#xD;
             2 dyspnea)&#xD;
&#xD;
          -  Ongoing infection NCI-CTCAE v.4.0 Grade &gt; 2&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with&#xD;
             antiviral therapy&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Patients with evidence or history of any bleeding diathesis, irrespective of severity&#xD;
&#xD;
          -  Any hemorrhage or bleeding event NCI-CTCAE v. 4.0 Grade &gt;= 3 within 4 weeks prior to&#xD;
             the start of regorafenib&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
          -  Dehydration NCI-CTCAE v.4.0 Grade &gt;= 1&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the program&#xD;
&#xD;
          -  Known hypersensitivity to regorafenib, the drug class, or excipients in the&#xD;
             formulation&#xD;
&#xD;
          -  Any illness or medical conditions that are unstable or could jeopardize the safety of&#xD;
             the patient and his / her compliance in the program&#xD;
&#xD;
          -  Interstitial lung disease with ongoing signs and symptoms&#xD;
&#xD;
          -  Persistent proteinuria of NCI-CTCAE v.4.0 Grade 3 (&gt; 3.5 g/24 hours)&#xD;
&#xD;
          -  Patients unable to swallow oral medications&#xD;
&#xD;
          -  Any malabsorption condition&#xD;
&#xD;
          -  Unresolved toxicity higher than NCI-CTCAE v.4.0 Grade 1 (excluding alopecia, anaemia,&#xD;
             and hypothyroidism) attributed to any prior therapy / procedure&#xD;
&#xD;
          -  Concomitant participation or participation within the last 30 days in a clinical trial&#xD;
&#xD;
          -  Non-permissible concomitant medications and procedures (systemic anti-cancer therapy&#xD;
             including cytotoxic therapy, signal transduction inhibitors, immunotherapy and&#xD;
             hormonal therapy or any experimental therapies; Tyrosine Kinase Inhibitors (TKIs);&#xD;
             bone marrow transplant or stem cell rescue; use of biologic response modifiers, such&#xD;
             as granulocyte colony stimulating factor (G CSF), within 3 weeks prior to entering the&#xD;
             program; St John's Wort; grapefruit and grapefruit juice; all traditional medicines&#xD;
             with an anti-cancer indication)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01689376
org study id: 16040
nct id: NCT01689376
lead sponsor: 
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed
      with metastatic and / or unresectable GIST who have progressed after standard therapy.
This "Managed Access Program" covers the different types of programs in the participating
      countries (including compassionate use program, named patient program, cohorts e.g. ATU in
      France, etc).
intervention type: Drug
intervention name: Regorafenib (BAY73-4506)
description: 160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
criteria: 
gender: All
minimum age: 18 Years
maximum age: 99 Years
last name: Bayer Study Director
role: Study Director
affiliation: Bayer
responsible party type: Sponsor
mesh term: Gastrointestinal Stromal Tumors